The addition of bevacizumab to trifluridine/tipiracil demonstrated a statistically significant and clinically meaningful improvement in OS vs. trifluridine/tipiracil alone among adults with refractory metastatic colorectal cancer.
The finding, presented at ASCO Gastrointestinal Cancers Symposium, represents a 39% reduction in the risk for death among this patient population.
“The prognosis for [patients with] metastatic colorectal cancer who do not respond to chemotherapy remains poor, with median survival times typically ranging from 4 to 8 months,” Josep Tabernero, MD, PhD, head